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Abstract 
Background: Mumps is an infectious and common disease during childhood. The vaccination against some 
epidemic diseases like mumps has been introduced in national program. This report describes the immunogenicity 
and efficacy of Hoshino strain of mumps (included in MMR vaccine) in Iran during 2 years. 
Methods: Three hundred and thirty eight children aged 3-18 years from Shahr-e-Kord, Iran were enrolled. They 
were tested for mumps IgG using enzyme-linked immunosorbent assay (ELISA). The percent of susceptible 
mumps IgG negative children was 19.8% (67 subjects), among them, 36 received the MMR vaccination and 
successfully completed the study. Blood sample was collected by venipuncture at 3, 12, and 24 months after 
vaccination and serum samples were tested by ELISA for detection of mumps IgM and IgG. 
Results: The seroconversion rate was 86.1%, 77.7% and 75% at 3, 12, and 24 months after vaccination respectively. 
Conclusion: Although the early serocoversion rate was high, but later it declined to a level of 75% which is the 
same immunity as natural infection which means that the immunity after vaccination would not last for long period 
of time and there may be a need for introduction of the booster dose of vacci 
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Introduction 
As in many other developing countries, mumps 
was one of the causes of morbidity among 
children in Iran. In March 2004, mumps 
immunization was integrated in the expanded 
program of immunization (EPI) combined with 
measles and rubella (MMR). 
Two previous studies carried out in Shiraz and 
Tehran in the Islamic Republic of Iran reported 
that 34.2% of the population in Shiraz study in 
southern Iran and 82.3% of 5-year-olds and 
29.4% of 10-year olds in Tehran study were 
seronegative against mumps.1,2 No other data on 
the community herd immunity against mumps or 
persistency of antibodies against Hoshino strain 
of mumps was available before this integration. 
Recently we conducted a study to determine the 
seroprevalence of mumps which indicated 
about 81.2% seropositivity against children 
aged 3-18 years in Shahr-e-Kord, Iran at 2004.3 
By considering the 18.8% seronegative children 
of general population and by integration of 
mumps vaccine in Iranian EPI and also no exact 
data on immunogenicity of Hoshino strain of 
mentioned mumps vaccine, for determining such 
obscure issue, (immunogenicity of Hoshino 
strain), we did a serial study. The main aim of 
these serial studies were to evaluate the 
immunogenicity, efficacy and long term 
immunity of the Hoshino strain of mumps 
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(included in MMR vaccine) against mumps in 
Shahr-e-Kord, Iran, during a period of 2 years 
after MMR vaccination in a group of 
seronegative susceptible children. 
Materials and Methods 
From January 2004 to December 2006 by 
coducting a serial studies in a selected group of 
children in Shahre-Kord, Iran, 3-18 years old 
children were selected from 158 schools and 100 
daycare centers by stratified random sampling 
method. The size of the sample in each stratum 
was taken in proportion to the size of the 
stratum. A sample size of 338 children aged 3-
18 years old were enrolled (56.5% boys).3 Data 
collection was based on an interview 
questionnaire and serology testing. The parents 
of selected children were given a formal 
invitation to attend the school where their 
consent to participation was obtained. We did 
not encounter any refusals and, with the  
cooperation of the manager of schools, all 
selected children participated in the study. The 
parents were interviewed by our co-investigator 
(a general practitioner) to collect data such as 
age, sex, history of previous exposure to mumps 
cases, history of previous mumps involvement 
and vaccination against mumps. 
In the first part of study,3 67 seronegative 
children were included. These 67 seronegative 
children were invited for MMR vaccination. 
Only 44 children completed our second study 
(vaccination with present MMR vaccine in Iran) 
to evaluate the immunogenicity 
of mumps Hoshino strain of MMR vaccination. 
In the day of vaccination, a blood sample was 
collected and then they were injected by MMR 
vaccination (time 0), and were followed up 3 
month (second part of study), 1 year (third part 
of study) and finally, at 2 years following 
vaccination (forth part of study) to find out the 
persistency of mumps antibodies. This means 
that blood specimens were collected on the 
day of vaccination (time 0) and then at 3, 12, 
and 24 months post-vaccination. Blood 
specimens were centrifuged and sera were stored 
in cryo-vials at -200C until all samples were 
tested simultaneously for mumps IgM and IgG 
(ELISA) kits manufactured by Trinity Biotech 
Capita, (Jamestown, USA, NY, 14701). All of 
them were tested simultaneously for IgG1 and 
IgM1 (at the day of vaccination), IgG2 and 
IgM2 (3 months), IgG3 and IgM3, (12 months) 
and IgG4 (24 months) following vaccination. 
The quality control was done simultaneously 
with the measurement of samples. Based on the 
recommendation of the kit, negative and positive 
control numbers and the mean values were in an 
acceptable range. Based on the kit definition, the 
results were calculated as antigen–antibody 
ratios, and recorded as positive or negative. 
Statistical analysis was performed based on 
using the SPSS software (version 11.5, Chicago, 
IL, USA). By using Fisher Exact and Cochran 
and Chi Square tests, p values less than 0.05 
were considered statistically significant. Due to 
nearly 100% seronegativity of IgM3 (IgM3 
means that the third time that we check the IgM) 
at the time of one year after vaccination, so the 
IgM4 (it means that IgM4 at the two years or  
last test) was ignored. Ethical approval for the 
study was obtained from the Ethical Committee 
of Shahr-e-Kord University of Medical 
Sciences, and referred to the local educational 
organization for approval. 
Results 
This is a cross-sectional stratified random 
sampling study conducted in Shahr-e-Kord, Iran 
during between Jan 2004 to Dec 2006. This 
study included 338 children (M to F=1.3) aged 
3-18 years who were tested for mumps IgG 
antibody by ELISA method.3 Of 338 children 
screened, 67 (19.8%) were mumps IgG negative 
thus indicating that they were susceptible. 
About 23% and 17.5% of girls and boys were 
mumps IgG negative respectively (p=0.226). 
Agespecific mumps IgG seroprevalence rose 
rapidly from 66.7% at age 7-11 years (primary 
schools) to 79.5% at age 12-14 years (guidance 
schools) and to 95.4% at age 15-18 years (high 
schools). Using χ2, there was a statistically 
significant difference between age and 
seroprevalence (p<0.001) (Table 1). 
Forty four mumps IgG negative subjects (from 
67 seronegative subjects in first part of study) 
accepted to be vaccinated with MMR vaccine to 
evaluate the immunogenicity of mumps Hoshino 
strain included in the MMR vaccine. From these 
44 persons, forty children were present till the 
end of study, among them four (10%) subjects 
were excluded due to seroconversion (new 
infection). Therefore 36 children successfully 
completed the study. Based on age, this study 
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included two groups of children of 6-11 years 
old (20 persons) and 12-14 years old (16 
persons). The seroconversion rate for 6-11 years 
old age group was 85% at 3 months. Mumps 
IgG was detected in 75% at 12 months and 24 
months postvaccination. Based on Cochran test, 
there was no significant difference (p=0.135). 
The seroconversion rate for 12-14 years old age 
group was 87.5% at 3 months. Mumps IgG was 
detected in 81.3% and 87.5% at 12 months and 
24 months post-vaccination respectively. 
This difference was not statistically significant 
(p=0.717). Two subjects developed parotiditis 
and fever, 7-31 days following vaccination and 
were confirmed by serology.4 The 
seroconversion rate was 86.1% (31/36) at 3 
months following vaccination, while this rate 
remained positive in 77.8% (28/36) and 80.6% 
(29/36) after one and two years respectively 
(p=0.247). IgM seropositivity was 0%, 17% and 
3% at the time of vaccination, 3 months and 12 
months following vaccination respectively and 
based on Cochran test, the change was 
significance (p=0.006). Among 20 persons aged 
6-11 years old, 2 seronegative IgM persons at 
the time of vaccination remained IgM positive 
in 3 months (IgM2) and one year (IgM3)  
following vaccination (p=0.135), but among 4 
persons of 12-14 years old, one person remained 
positive at 12th month (IgM3) (p=0.039). 
Based on sex (gender), there was no significant 
difference for IgM3 (p=0.389), but there was a 
difference for IgM2 of male and female 
(p=0.024), so that IgM2 was positive more in 
males than females at 3 months following 
vaccination. Based on the Fisher Exact test, no 
significant difference was noticed for age and 
these tests (p= 0.374 for age and IgM2 and 
p=0.444 for age and IgM3). Review of IgG at 
each section of study showed a 86.1% (31/36) 
seroconversion at 3 months following 
vaccination, of these seroconverted persons 
(28/31, 90.3%) remained seropositive 
and immune at 24th month following 
vaccination. 
Review of reaction of IgG during 2 years period 
of study showed that among 36 seronegative IgG 
persons, seronegativity was as follows: 14% 
(5/36) due to vaccine failure at 3rd month while 
became seronegative in 3/36 (8%) at one year 
and 1/36(3%) at 24th month following 
vaccination. 
Based on gender, there was no significant 
difference for IgG2, IgG3 and IgG4 (p>0.99) 
based on Fisher Exact test. In fact, the rate of 
Immunogenicity and efficacy of the Hoshino 
strain of mumps (included in MMR vaccine) 
against mumps in Shahr-e-Kord, Iran was 
reported to be 80.6% (29/36), 2 years after 
vaccination. 
 
Discussion 
Since early Iranian calendar year of 1383 (20th 
March 2004), the MMR vaccination was 
introduced in national vaccination program. This 
vaccine contains Hoshino strain of mumps. In 
Iran, there is not report about the persistency of 
antibodies against this strain yet. In fact, the 
main purpose of this study was to determine the 
persistent mumps antibodies up to two years 
after MMR vaccination, in national vaccination 
program, so that to clear if any booster vaccine 
is needed in future. But a matter of question is 
that, it is not clear why the present age groups 
(12 months and 4–6 years old) were selected for 
mumps vaccination in Iranian EPI. One reason 
may be the convenience of the simultaneous 
administration of measles and rubella. Our first 
study found a seronegativity rate of 19.8%, 
which is lower than the rates reported in 
previous Iranian studies (34.2% and 29.4%),1,2 
but similar to the rate reported in Izmir, Turkey 
(20.1%).5 However, wide discrepancies can 
occur like the Turkish study that reported 
a rate of only 10.9%.6 In our first (screening) 
part of study, the age specific seropositive rate 
rose rapidly from 66.7% at age 7-11 years to 
79.2% at age 12-14 years and 95.4% at age 15–
18 years. The rate of individuals in a population 
with doubtful protection (unvaccinated, non-
responder and low responder after primary 
vaccination) prevented to reach the herd 
immunity of 95% necessary for elimination of 
an infectious disease. 7 In the normal population, 
there was a herd immunity against infection, 
which was acquired by either natural infection, 
or by vaccination. Any vaccination program 
must have a high seroconversion rate 
accompanied by long time persistency to keep 
this herd immunity of 95%. There are some 
controversial reports about the antibodies 
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persisted against mumps. A study showed 
antibody in human subjects persisted without 
substantial decline for 8 years after mumps 
vaccination (Jeryl Lynn strain), for 5 years after 
measles-mumps-rubella and mumps-rubella 
combined vaccines, and for 2 years after 
measles-mumps vaccines, the longest periods 
tested.8 Another study showed that 
seroconversion rate, magnitude of antibody 
titers, and incidence of clinical reactions 
following the trivalent vaccination include 
mumps Hoshino strain were similar to those 
occurring after the monovalent mumps Hoshino 
strain vaccination.9 Sometimes persistence of 
antibodies depends on the viral strain. A study 
reported that children given MMR vaccine 
containing the Urabe mumps strain were less 
likely to be antibody negative than those given 
the Jeryl Lynn mumps strain (39/266, 15% vs 
39/204, 19%, p=0.048).10 A study on  
seroconversion and two vaccine protocol 
reported that in seronegative vaccines, the 
seroconversion rate was 86%. The antibody 
levels fell rapidly within the first year of 
follow-up, but remained relatively stable in 
subsequent years. After revaccination, the 
seropositivity rate was 95% and declined more 
slowly thereafter to 86% at year 9 of follow-up. 
The mean antibody titer was significantly 
(p<0.05) higher 4 years after the second MMR 
vaccination when compared with the 
corresponding time point after the first 
vaccination.11 But sometimes the age affect the 
seronegativity. The levels of antibody against 
measles, mumps, and rubella were determined at 
5-6 years postimmunization in 468 children 
vaccinated with two different trivalent vaccines. 
The proportions of children without detectable 
antibody levels were 12 and 3.6% for measles 
(p<0.001), 14.9 and 7% for mumps (p=0.006), 
and 3.3 and 3.1% for rubella (p=0.88), 
respectively, in MMR II and Trivirix recipients.  
A higher proportion of those vaccinated at 
younger ages had undetectable or low levels of 
measles antibody. These data indicate that a 
large proportion of children vaccinated under 
routine conditions did not have detectable 
measles and mumps antibody.12 Also a study 
indicated that some seronegative persons may be 
due to primary vaccination failures.3 In 
conclusion, the persistency of antibodies may 
be dependent on the monovalent or trivalent8,9 
mumps strain10 or time point after the first 
vaccination,1 which can vary with age of 
person.12,13 Our first screening study showed that 
338 patients (19.8%) were seronegative against 
mumps.3 These seronegative persons were 
vaccinated with current MMR vaccine of Iranian 
national program. There was a seroconversion 
rate of 86% in our second study (three month 
post vaccination). Although there was a 
relatively a high rate of immunity against 
mumps strain, but later reduction in persistence 
antibodies within next years, resulted to level of 
immunity below 95% rate of herd immunity 
which was needed to eradicate mumps. 
This study reported a 86% seroconversion rate 
following post-vaccination of Hoshino strain of 
mumps (included in MMR). The vaccine failure 
was about 14% and although 86% were 
seroconverted immediately post-vaccination 
immunity, but they waned and only 75% of 
children remained immune at the 24 months 
follow-up. Thus, one forth of children was 
susceptible to mumps. This is in line with the 
Ministry of Health and Education of Iran 
strategy to conduct a nationwide survey to 
confirm this level of immunity, and to change 
the strain of mumps included in MMR vaccine 
of Iran. 
In the case of confirmation of such finding in 
next larger studies, it could be suggested to 
another booster dose of mumps vaccine in 
children vaccination very soon (for example 1-2 
months) after vaccination (due to 14% vaccine 
failure) or two years after first vaccination (due 
to decreasing level of immunity to 75% at this 
time). 
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